Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Purchases C$51,332.82 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh bought 22,222 shares of the stock in a transaction on Monday, April 15th. The shares were acquired at an average cost of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Trading Down 3.8 %

Fennec Pharmaceuticals stock opened at C$13.77 on Friday. The company has a debt-to-equity ratio of 881.09, a current ratio of 3.29 and a quick ratio of 10.17. The company has a market capitalization of C$372.34 million, a price-to-earnings ratio of -13.50 and a beta of 0.35. Fennec Pharmaceuticals Inc. has a one year low of C$9.27 and a one year high of C$15.43. The company’s fifty day moving average price is C$13.52 and its two-hundred day moving average price is C$12.63.

Fennec Pharmaceuticals (TSE:FRX) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing the consensus estimate of C$0.02 by C($0.16). The business had revenue of C$13.25 million for the quarter, compared to analyst estimates of C$12.88 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. On average, analysts forecast that Fennec Pharmaceuticals Inc. will post 0.4202312 earnings per share for the current fiscal year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.